Cancer Drug Pulled From Market Over Safety Concerns

Cancer Drug Pulled From Market Over Safety Concerns

(MedPage Today) -- The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is discontinuing all active...

Ipsen to withdraw cancer drug acquired in buyout due to safety concerns

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell.

Safety concerns prompt Ipsen to pull Tazverik from market

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

Ipsen withdraws cancer drug following safety concerns - European Biotechnology Magazine

Ipsen has announced the immediate withdrawal of its cancer drug Tazverik across all indications after serious safety issues emerged in an ongoing Phase III trial. The post Ipsen withdraws cancer drug following safety concerns appeared first on European Biotechnology Magazine.

Tazemetostat Pulled From Market Over Secondary Cancer Risk

Options remain for patients with relapsed/refractory follicular lymphoma, but tazemetostat was the only drug approved specifically for epithelioid sarcoma.

Ipsen pulls cancer drug from market over safety risks

Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...